Aytu BioPharma (AYTU) Competitors $2.63 -0.02 (-0.75%) Closing price 04:00 PM EasternExtended Trading$2.58 -0.05 (-2.05%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, BMEA, VNRX, and INCRShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), Biomea Fusion (BMEA), VolitionRx (VNRX), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors Verrica Pharmaceuticals Adaptimmune Therapeutics Milestone Pharmaceuticals Surrozen Pyxis Oncology Alto Neuroscience Maxpro Capital Acquisition Biomea Fusion VolitionRx InterCure Aytu BioPharma (NASDAQ:AYTU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings. Do analysts prefer AYTU or VRCA? Aytu BioPharma presently has a consensus price target of $10.00, suggesting a potential upside of 280.23%. Verrica Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 21.03%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Aytu BioPharma is more favorable than Verrica Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do insiders and institutionals have more ownership in AYTU or VRCA? 33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 3.6% of Aytu BioPharma shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, AYTU or VRCA? Aytu BioPharma has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Does the media favor AYTU or VRCA? In the previous week, Aytu BioPharma and Aytu BioPharma both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Aytu BioPharma's score of 0.94 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is AYTU or VRCA more profitable? Aytu BioPharma has a net margin of 2.37% compared to Verrica Pharmaceuticals' net margin of 0.00%. Aytu BioPharma's return on equity of 3.51% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aytu BioPharma2.37% 3.51% 0.91% Verrica Pharmaceuticals N/A N/A -145.63% Which has preferable earnings and valuation, AYTU or VRCA? Aytu BioPharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAytu BioPharma$81.66M0.29-$15.84M-$0.72-3.65Verrica Pharmaceuticals$7.18M85.16-$76.58M-$1.20-5.51 SummaryAytu BioPharma beats Verrica Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.61M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-3.6521.1828.1120.03Price / Sales0.29339.43461.37103.88Price / CashN/A43.2336.5559.01Price / Book0.578.368.655.90Net Income-$15.84M-$55.19M$3.25B$258.66M7 Day Performance10.97%5.89%4.20%2.23%1 Month Performance22.33%17.63%10.82%12.76%1 Year Performance-2.59%5.09%34.70%19.36% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma4.135 of 5 stars$2.63-0.8%$10.00+280.2%-3.6%$23.61M$81.66M-3.65160VRCAVerrica Pharmaceuticals4.1329 of 5 stars$0.82+1.0%$8.00+881.6%-90.2%$75.38M$7.57M-0.6840Positive NewsGap DownADAPAdaptimmune Therapeutics1.9629 of 5 stars$0.28+4.6%$1.35+381.0%-73.0%$74.48M$178.03M-1.04490News CoverageMISTMilestone Pharmaceuticals2.8103 of 5 stars$1.38-11.5%$7.00+407.2%+6.1%$73.78M$1M-1.7730High Trading VolumeSRZNSurrozen2.7641 of 5 stars$8.61-1.1%$38.50+347.2%+5.3%$73.73M$11.64M-0.3480Positive NewsPYXSPyxis Oncology2.4157 of 5 stars$1.19+2.6%$9.00+656.3%-64.5%$73.72MN/A-0.7560ANROAlto Neuroscience2.4036 of 5 stars$2.71+4.0%$8.50+214.2%-79.4%$73.22MN/A-1.16N/ATrending NewsJMACMaxpro Capital AcquisitionN/A$5.45-4.4%N/A+2,812.2%$73.18MN/A0.002,021Gap UpBMEABiomea Fusion3.2899 of 5 stars$1.94-3.0%$21.40+1,003.1%-66.8%$72.89MN/A-0.5550Upcoming EarningsVNRXVolitionRx1.5738 of 5 stars$0.68+2.5%$3.50+411.2%-1.9%$71.20M$1.31M-1.9080INCRInterCure0.6636 of 5 stars$1.55flatN/A-34.5%$70.63M$238.85M0.00350Positive News Related Companies and Tools Related Companies Verrica Pharmaceuticals Alternatives Adaptimmune Therapeutics Alternatives Milestone Pharmaceuticals Alternatives Surrozen Alternatives Pyxis Oncology Alternatives Alto Neuroscience Alternatives Maxpro Capital Acquisition Alternatives Biomea Fusion Alternatives VolitionRx Alternatives InterCure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.